Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The protective effect of rheumatic disease agents in COVID-19

María O. Valenzuela-Almada, Michael S. Putman, Ali Duarte-García

Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, USA

Keywords: COVID-19, Corticosteroids, IL-6 inhibitors, IL-1 inhibitors, TNF inhibitors, JAK inhibitors

Abstract

Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-α) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants.

Introduction

The severe acute respiratory coronavirus 2 (SARS-CoV-2), discovered in late 2019, is the etiologic agent of the pandemic coronavirus disease 2019 (COVID-19) [1]. The disease course of COVID-19 ranges from asymptomatic or mild upper respiratory symptoms to the acute respiratory distress syndrome (ARDS) [2]. In severe COVID-19 cases, the host immune response is thought to play a role in the pathophysiological mechanisms that lead to ARDS and multisystem organ failure (MSOF). Features of exuberant immune activation have been described and critical cases may resemble macrophage...
activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis (sHLH). Such “cytokine storm” syndromes typically present with elevated levels of serum ferritin and d-dimer, lymphopenia (including low natural killer (NK) and cytotoxic T cells), and elevated pro-inflammatory cytokines, including interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α), and interleukin-8 (IL-8) [3,4].

In an effort to curb inappropriate immune activation, several immunosuppressive therapies have been investigated as potential treatments for cases of severe COVID-19, including corticosteroids, IL-6, IL-1, Janus kinase (JAK), and TNF-α inhibitors [5–9].

Many of these agents have been investigated for septic shock, including steroids, TNF inhibitors, and IL-1 inhibitors [10–12]. In addition, targeted therapies have been used in hyperinflammatory conditions, such as adult onset Still’s disease and chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome (CRS). Finally, though they have not been studied for hyperinflammatory conditions, JAK inhibitors are used in the treatment of autoimmune diseases, and it has been speculated that may inhibit AAK1, which could theoretically impair SARS-CoV-2 entry into human cells [8].

The aim of this narrative review is to analyze the mechanistic rationale and available evidence for selected anti-rheumatic drugs for the treatment of COVID-19. The data for this review were obtained from searches of Medline/PubMed as well manual searches of the coronavirus resource sites and collections of The Lancet, New England Journal of Medicine, Journal of the American Medical Association, British Medical Journal, and Annals of Internal Medicine. We prioritized peer-reviewed publications, systematic reviews with meta-analyses and randomized controlled trials (RCTs). Additionally, we summarized the ongoing active RCTs on phases 3–4 to reflect the current research efforts related to these drugs.

**Corticosteroids**

Corticosteroids have been widely used for rheumatologic diseases, hyperinflammatory conditions, and in patients with MSOF. These lipophilic molecules activate cytoplasmic receptors that in turn translocate to the nucleus and alter several genes implicated in the inflammatory response. As non-selective immunosuppressive agents, they modify the expression of pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-α and interferon-γ [IFN-γ]), inhibit leukocyte migration to tissues, and upregulate anti-inflammatory genes [13]. Given their broad availability and wide ranging effects, corticosteroids have been investigated as treatments for dysregulated immune responses in severe sepsis, septic shock, bacterial pneumonia, and ARDS. On balance, RCTs have been equivocal or have suggested a small benefit. Notably, in a large RCT hydrocortisone decreased respiratory mortality in severe bacterial pneumonia [14] and in another fludrocortisone decreased mortality in septic shock [10]. Others have been equivocal, demonstrating no benefit in 90-day mortality for hydrocortisone [15] and only marginal improvement in outcomes with respect to ARDS [16,17]. A high-quality systematic review and meta-analysis found that the use of corticosteroids may result in a small reduction in mortality in patients with sepsis [18]. Beside sepsis, corticosteroids are also used as a first-line therapy in hyperinflammatory conditions, including sHLH, adult onset Still’s disease (AOSD), and CRS, among others [19–21].

Corticosteroids have been used off label for COVID-19 since the beginning of the pandemic, and multiple observational studies have been published to date. Early observational data were largely conflicting, with suggestions of decreased mortality in patients with COVID-19–induced ARDS [22,23], increased mortality or intensive care unit (ICU) admission [24–26], and prolonged viral shedding. Such discrepancies led to recommendations against the routine use of corticosteroids in World Health Organization (WHO) guidelines [27] and cautious endorsement of selective use by critical care societies [28] and infectious disease societies [29].

More recently, robust clinical evidence in favor of corticosteroid use among patients with severe COVID-19 has emerged. First, the adaptive RECOVERY trial from the United Kingdom demonstrated that the use of 6 mg of dexamethasone daily resulted in a decrease in 28-day mortality among patients who required mechanical ventilation (rate ratio, 0.64; 95% CI, 0.51–0.81) or supplemental oxygen (rate ratio, 0.82; 95% CI, 0.72–0.94). It should be noted that dexamethasone showed no benefit — and possible harm — among those patients who did not require respiratory support (rate ratio, 1.19; 95% CI, 0.91–1.55) [5].
Further evidence supporting the conclusions of the RECOVERY trial has since emerged. These include other multicenter randomized clinical trials (DEXA-COVID-19 [16], CoDEX [30], CAPE COVID [31], REMAP-CAP [32] and GLUCOVID [33], Steroids Sari, and COVID STEROID) that evaluated different corticosteroid regimens within different populations. In a systematic review and meta-analysis, this body of evidence suggests a benefit with regard to 28-day all-cause mortality (odds ratio (OR) 0.66; 95% CI, 0.53–0.82; \( P < 0.001 \)) that is maintained across multiple subgroups of patients, including older and younger patients, men and women, and different durations of symptoms. Furthermore, this new evidence has confirmed that the protective effect is a class effect rather than one limited to dexamethasone. In light of these data, corticosteroid use has become the standard of care in severe and critical COVID-19 [34].

Despite these encouraging data, reasons for caution remain. First, corticosteroids are not a panacea or cure, and many patients who receive them will still suffer ARDS, MSOF, and death. The trials have followed patients for a short period of time, therefore, the long-term effects of steroids on mortality and functional outcomes have not been defined. Second, the long-term effects of glucocorticoid use, such as weight gain, hyperglycemia, and bone fragility, were not assessed in time-limited clinical trials. Such adverse events are expected to be minimal given a short course of glucocorticoid therapy, but care should be taken to minimize unnecessary exposure. Third, supraphysiologic baseline glucocorticoid use (prednisone > 10 mg/day) increased the risk of hospitalization of COVID-19 patients [9] highlighting the need for robust immunity early in COVID-19 infection to control viral spread. Finally, no data support the use of glucocorticoids in asymptomatic or mild disease.

**Interleukin-6 inhibitors**

A strong rationale for investigating IL-6 inhibitors also exists. IL-6 exerts pleiotropic effects in adaptive and innate immune cells. IL-6 plays a central role in promoting the secretion of other cytokines and growth factors — vascular endothelial growth factor and interleukin-8, for instance — and has been implicated in cytokine storm syndromes [3]. In fact, the IL-6 inhibitor tocilizumab, a humanized monoclonal antibody directed against the IL-6 receptor, is approved by the Federal Drug Administration (FDA) for the treatment of systemic juvenile idiopathic arthritis (SJIA) and CRS induced by CAR T cell therapy [35]. The hyperinflammatory phenotype of COVID-19 resembles CRS, and elevated IL-6 levels have been observed in severe COVID-19 [36], which are associated with a worse prognosis [4,37].

Observational data have lent support to this proposed potential benefit. The largest published study of which we are aware evaluated 544 patients with severe COVID-19 [38]. After adjustment for sex, age, and disease severity, receiving the IL-6 inhibitor tocilizumab was associated with a reduction in mortality (adjusted hazard ratio (HR) 0.61, 95% CI 0.40–0.92). A smaller study that compared treatment with glucocorticoids with or without tocilizumab to age and sex-matched historical controls also suggested a reduction in mortality (HR: 0.35; 95% CI 0.19–0.65). A large body of small observational studies without comparator groups has been largely unrevealing and should not be used to draw inferences with regard to tocilizumab [6,39–45]. Observational data assessing the IL-6 receptor antagonist sarilumab have been similarly flawed and inadequate for evaluating its potential efficacy [46,47].

More importantly, large RCTs assessing the effect of IL-6 inhibition of severe COVID-19 have recently been completed. In a July 29th press release regarding the results of the phase 3 global RCT COVACTA, tocilizumab, did not achieve its primary endpoint of improvement in clinical status (\( p = 0.36; \) OR = 1.19 [0.81–1.76]) or the secondary endpoint of decrease in mortality at week 4 (19.7% mortality in experimental group vs 19.4% in control group). However, in a more recent press release of the phase 3 RCT EMPACTA, tocilizumab decreased the probability of progression to mechanical ventilation or death (\( p = 0.348; \) HR = 0.56 [0.32, 0.97]), but there were no statistical differences in mortality alone [48]. Peer-reviewed publication of both trials is pending [49]. Similarly, preliminary findings from an adaptive phase 2/3 trial of the IL-6 receptor antagonist sarilumab have been discouraging and enrollment has been stopped [50].

In Table 1, we summarized the active trials assessing tocilizumab, sarilumab, and other IL-6 agents (siltuximab [51] and olokizumab), which are expected to be published in the near future. Current guidelines recommend against the use of IL-6 inhibitors outside of clinical trials [52].
Interleukin-1 inhibitors

The earliest suggestions of immunosuppression in COVID-19 considered IL-1 antagonists [53]. IL-1 is secreted after viral activation of Toll-like receptors in macrophages, monocytes, and dendritic cells, and leads to the formation of the inflamasome. There are two main forms of IL-1: IL-1α and IL-1β.
When binding to the IL-1 receptor type 1 (IL-1R1), IL-1β, released by monocytes, macrophages, and neutrophils, has a protagonist role in viral infections, mediating neutrophil recruitment and inflammation, fever, and severe respiratory problems [54,55]. Moreover, this IL-1/Inflammasome signaling pathway is involved in lung dysfunction in influenza-induced chronic obstructive lung disease exacerbations [56] and for the pathology seen in fulminant viral hepatitis [57]. This pathophysiologic rationale has been supported by studies of cells infected with SARS-CoV, which found high secretion of IL-1β by immune cells, thus potentially leading to lung damage and increased disease severity [58].

The majority of studies to date have assessed the recombinant version of the human IL-1 receptor antagonist protein, anakinra. Anakinra is approved by the FDA for the treatment of autoinflammatory conditions, such as cryopyrin-associated periodic syndromes (CAPS), and was recently approved for AOSD [59]. Moreover, it has been widely used off-label for sHLH [59]. Small case series have suggested potential efficacy for anakinra in moderate to severe COVID-19 [7,60-64].

Larger cohort studies have also been published. Most notably, in a cohort study that included 52 anakinra-treated patients and 44 historical controls, anakinra use was associated with a lower risk of mechanical ventilation or death (HR 0.22 95% CI 0.10–0.49). However, a high percentage of patients in both groups were receiving other agents [65]. In another retrospective cohort, which compared 29 patients (with moderate COVID-19 requiring non-invasive ventilation) treated with high-dose intravenous anakinra and seven patients with low-dose subcutaneous anakinra to a standard treatment control group, only high-dose anakinra was associated with a higher survival rate at 21 days (90% vs 50% survival rate, HR: 0.20; CI 95% 0.04–0.63). It should be noted that 24% of patients treated with high doses of anakinra developed adverse effects that required discontinuation of the drug, including bacteremia and elevations in liver enzymes [7]. In a meta-analysis of both studies, anakinra was associated with a significantly lower risk of mortality (pooled HR: 0.2; CI 0.1–0.4) [66]. Table 2 summarizes the ongoing actively recruiting, phase 3 or 4 clinical trials using anakinra.

Rilonacept and canakinumab are other IL-1 antagonists. Rilonacept is a soluble decoy factor that binds directly to IL-1α and IL-1β, while canakinumab is a human anti-IL-1β antibody. Both are also approved for the treatment of CAPS, and canakinumab is also approved for SJIA and other periodic fever syndromes [67]. There is one retrospective analysis of 10 patients with COVID-19 pneumonia, acute hypoxemic respiratory failure, and elevated C-reactive protein (CRP), who were treated subcutaneously with a single dose of canakinumab. This study observed that canakinumab administration was associated with a rapid decrease of CRP levels and an improvement in oxygenation, but such observational studies require further validation [68]. Currently, there are no registered clinical trials evaluating rilonacept and there is one actively recruiting phase 3 evaluating canakinumab. IL-1 inhibitor use should remain in the context of clinical trials until more robust evidence is available.

Janus kinase inhibitors

Cytokine-mediated activation of the JAK-STAT (Janus-kinases-signal transducer and activator of transcription proteins) pathway is critical in the immune response, and JAK inhibitors have also been considered for COVID-19. As with IL-1 and IL-6 inhibitors, it has been hypothesized that inhibition of the JAK-STAT pathway could lead to decrease of cytokine-mediated inflammation [4]. At the same time, inhibition of the interferon pathway by JAK-STAT inhibitors may be counterproductive, as IFN signaling may be necessary to clear viral infections [69]. In addition to immunomodulatory effects, JAK inhibitors may inhibit the AP2-associated protein kinase 1 (AAK1). Both kinases are key regulators of clathrin-mediated endocytosis, a mechanism used by COVID-19 to enter and infect cells. Therefore, inhibition of these kinases may also interrupt viral entry to target cells and intracellular assembly of the virus [8,70].

In a recent meta-analysis of JAK inhibitors and interferon, five studies evaluating JAK inhibitors were promising (3 baricitinib and 2 ruxolitinib). Overall, JAK inhibitor or INF treatment was associated with lower odds of mortality (OR, 0.12; 95% CI, 0.03–0.39; p = 0.0005), lower odds of ICU admission, (0.05; 95% CI, 0.01–0.26; p = 0.0005) and higher odds for discharge (OR, 22.76; 95% CI, 10.68–48.54; p < 0.00001) [71]. However, this meta-analysis has not been peer-reviewed and there was high heterogeneity among the studies, including differences in therapies, patient characteristics, and the study type.
Individual results from two small RCTs with ruxolitinib in the setting of severe COVID-19 also found some improvement in clinical outcomes [72,73]. Recently, a press release of the Adaptive COVID-19 Treatment Trial-2 study noted a small benefit with respect to baricitinib in combination with remdesivir, which reduced median recovery time by one day. Results regarding mortality and safety are pending [74]. Currently, there are no late phase trials for tofacitinib. Results from ongoing clinical trials are needed to make a recommendation regarding the use of these drugs (Table 3).

Tumor necrosis factor inhibitors

TNF-α is a key cytokine in the pro-inflammatory host response to COVID-19. Aside from its pathological implication in the COVID-19 complications, TNF-α is critical for promoting viral cell entry. The virus spike protein is able to induce TNF-α release by inducing TNF-α-converting enzyme activity, a process that facilitates viral entry [75]. Thus, TNF-α inhibitors (infliximab, etanercept, adalimumab, golimumab, and certolizumab) have been suggested to have a role in the prevention of SARS-CoV-2 infection and subsequent inflammatory consequences.

Interestingly, data from the COVID-19 Global Rheumatology Alliance showed that patients treated with anti-TNF-α agents for other autoinflammatory and rheumatologic diseases experienced a lower rate of hospitalization (OR, 0.40; 95% CI 0.19–0.81) [9]. Moreover, a decrease in cytokine levels was seen in a small case series of patients with severe COVID-19 treated with infliximab [76]. Other case reports

Table 2
Ongoing phase 3 or 4, currently recruiting randomized clinical trials of IL-1 Inhibitors.

| Drug       | Title                                                                 | Design                        | ClinicalTrials.gov Identifier |
|------------|-----------------------------------------------------------------------|-------------------------------|-------------------------------|
| Anakinra   | Efficacy and Safety of ANAkinra During Adult “COVID-19” With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial (ANACONDA) | Open label RCT | NCT04364009 |
| Anakinra   | Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1 (IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection (ANA-COVID-GEAS) | Open label RCT | NCT04443881 |
| Anakinra   | A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1 (IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection | Open label RCT | NCT04324021 |
| Anakinra   | A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome | Open label RCT | NCT04330638 |
| Anakinra   | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) | Open label RCT | NCT02735707 |
| Canakinumab| Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CANC-COVID) | Double-blinded placebo-controlled RCT | NCT04362813 |

Abbreviations: IL-1, interleukin 1; RCT, randomized controlled trial; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
of patients previously taking anti-TNF-α inhibitors have also suggested a protective effect for COVID-19 pneumonia [77–79]. Currently, there are no active phase 3 or 4 trials for TNF inhibitors. A phase 2 clinical trial of infliximab in the United States is ongoing. Given the paucity of data, TNF inhibitors should not be used in routine COVID-19 care.

**Summary**

Multiple immunosuppressive medications are under investigation for the treatment of coronavirus disease 2019 (COVID-19). High-quality evidence and clinical practice recommendations support the use of corticosteroids in severe or critical COVID-19. Observational data with interleukin 6 (IL-6) inhibitors have been promising, but recent press releases have had mixed reports and the full peer-reviewed reports have not been published. Similarly, observational studies suggest a benefit from IL-1 and tumor necrosis factor (TNF) inhibitors, but evidence from randomized controlled trials (RCTs) has yet to be published. JAK-STAT inhibitors have emerged as a potential therapeutic option, and a preliminary report from a trial of baricitinib in combination with remdesivir suggests a small benefit. Multiple phase 3 trials are currently ongoing to evaluate these and other immunosuppressive therapies.

**Practice points**

- Corticosteroids are recommended in current guidelines for severe and critical coronavirus disease 2019 (COVID-19).
- For patients with non-severe COVID-19, immunosuppressive therapy is not recommended.
- There is a paucity of evidence regarding the use of other anti-rheumatic disease therapies, which should be used within the context of ongoing RCTs.

**Research agenda**

- Evidence from ongoing placebo-controlled clinical trials is needed to determine the role of interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-α) inhibitors in the prevention or treatment of coronavirus disease 2019 (COVID-19).
Funding

MSP is supported by a Rheumatology Research Foundation Scientist Development Award; AD is supported by the CDC (grant number U01 U01DP006491), the Rheumatology Research Foundation Scientist Development Award, the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, the Women’s Health Career Enhancement Award and the Eaton Family Career Development Award.

Declaration of competing interest

The authors report no conflicts of interest.

References

[1] Paules CI, Marston HD, Fauci AS. Coronavirus infections—more than just the common cold. JAMA 2020;323(8):707–8.
[2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
[3] Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368(6490):473–4.
[4] Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620–9.
[5] Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa201436 [in press].
[6] Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U.S.A. 2020;117(20):10970–5.
[7] Cavalli G, De Luca G, Campochiario C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020;2(6):e325–31.
[8] Zhang X, Zhang Y, Qiao W, et al. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharm 2020;86:106749.
[9] Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020;79(7):859–66.
[10] Annane D, Renaut A, Bellissant E. Glucocorticoids with or without fludrocortisone in septic shock. N Engl J Med 2018;379(9):895–9.
[11] Qiu P, Cui X, Sun J, et al. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med 2013;41(10):2419–29.
[12] Pruitt JH, Copeland 3rd EM, Moldawer LL. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock. Shock 1995;3(4):235–51.
[13] Strehl C, Ehlers L, Gaber T, Buttgerer F. Glucocorticoids—all-rounders tackling the versatile players of the immune system. Front Immunol 2019;10:1744.
[14] Confolanieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171(3):242–8.
[15] Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018;378(9):797–808.
[16] Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020;8(3):267–76.
[17] Meduri GU, Bridges L, Shih MC, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med 2016;42(5):829–40.
[18] Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. Crit Care Med 2018;46(9):1411–20.
[19] Jamilouxy Y, Gerraud-Valentin M, Henry T, Seve P. Treatment of adult-onset Still’s disease: a review. Therapeut Clin Risk Manag 2015;11:33–43.
[20] Skinner J, Yankey B, Shelton BK. Hemophagocytic lymphohistiocytosis. AACN Adv Crit Care 2019;30(2):151–64.
[21] Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheum 2017;69(6):1135–43.
[22] Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):934–43.
[23] Fadel R, Morrison AR, Vahia A, et al. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 2020;71(16):2114–20.
[24] Lu X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146(1):110–8.
[25] Lu X, Chen T, Wang Y, et al. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Crit Care 2020;24(1):241.
Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ (Can Med Assoc J) 2020;192(27):E756–67.

Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. Br Med J 2020;369:m1936.

Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020;46(5):854–87.

Bhimraj AM, Shumaker R, Lavergne AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis 2021.

Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. Jama 2020;324(13):1307–16.

Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. Jama 2020;324(13):1298–306.

Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. Jama 2020;324(13):1317–29.

Corral L, Bahamonde A, Arnaez delas Revillas F, et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv 2020;2020.06.17.20133579.

Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama 2020;324(13):1330–41.

ACTEMRA® (tocilizumab). U.S. Food and Drug Administration website [package insert]. www.accessdata.fda.gov/ drugsatfda_docs/label/2019/020272s082,020588s070,021444s056lbl.pdf. [Accessed 20 August 2020].

Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71(15):762–8.

Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(5):846–8.

Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2(8):e474–84.

Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92(7):814–8.

Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Maladies Infect 2020;50(5):397–400.

Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol 2020;127:104380.

Michot JM, Albigeois L, Chaput N, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92(11):2368–70.

Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 2020;79(10):1277–85.

Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. 2020 [press release].

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. 2020 [press release].

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S trial in COVID-19 patients. July 2 2020 [press release].

Palanques-Pastor T, López-Briz E, Poveda Andrés JL. Involvement of interleukin 6 in SARS-CoV-2 infection: silatuximab as a therapeutic option against COVID-19. Eur J Hosp Pharm 2020;27(5):297–8.

(NIH) NLoH. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) treatment guidelines. 2021.

Mehta P, McCauley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–4.

Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020;34(2):327–31.

Calabrese LH, Calabrese C. Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: the role of interleukin 1. Cleave Clin J Med 2020.

Sichelstiel A, Yadava K, Trompette A, et al. Targeting IL-1β and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammation. PLoS One 2014;9(2):e84440.

Guo S, Yang C, Diao B, et al. The NLRP3 inflammasome and IL-1β accelerate immunologically mediated pathology in experimental viral fulminant hepatitis. PLoS Pathog 2015;11(9):e1005155.

He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol 2006;208(3):288–97.

Kinaret (anakinra). U.S. Food and Drug Administration website [package insert]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s013s040lbl.pdf. [Accessed 16 August 2020].

Navarro-Millán I, Sattui SE, Lakanpal A, et al. Use of anakinra to prevent mechanical ventilation in severe COVID-19: a case series. Arthritis Rheum 2020;72(12):1990–7.
[61] Aouba A, Baldolli A, Geffray L, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis 2020;79(10):1381–2.

[62] Pontali E, Volpi S, Antonucci G, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol 2020;146(1):213–5.

[63] Figuero-Pérez I, Olivares-Hernández A, Escala-Cornejo RA, et al. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab. Reumatol Clínica 2020. https://doi.org/10.1016/j.reumae.2020.06.008 [in press].

[64] Gonzalez-Garcia A, Garcia-Sánchez I, Lopes V, et al. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment. Rheumatology 2020;59(8):2171–3.

[65] Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020;2(7):e393–400.

[66] Putman M, Chock YPE, Tam H, et al. Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheum 2020;73(1):36–47.

[67] ILARIS (canakinumab). U.S. Food and Drug Administration website [package insert]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf. [Accessed 1 September 2020].

[68] Ucciferri C, Auricchio A, Di Nicola M, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol 2020;2(8):e457–8.

[69] Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis 2020;20(9):1012–3.

[70] Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020;20(4):400–2.

[71] Walz L, Cohen AJ, Rebaza AP, et al. Janus kinase-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. MedRxiv 2020.

[72] Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020;146(1):137–46. e3.

[73] Guidice V, Pagliano P, Vatrella A, et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol 2020;11:857.

[74] Baricitinib in combination with remdesivir reduces time to recovery in hospitalized patients with COVID-19 in NIAID-sponsored ACTT-1 trial. 2020 [press release].

[75] Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci U.S.A. 2008;105(22):7809–14.

[76] Stallmach A, Kortgen A, Gonnert F, et al. Infliximab against severe COVID-19–induced cytokine storm syndrome with organ failure—a cautionary case series. Crit Care 2020;24(1):444.

[77] Kunisaki R, Tsukiji J, Kudo M. Potential inhibition of COVID-19–driven pneumonia by immunosuppressive therapy and anti-TNFα antibodies: a case report. J Crohns Colitis 2020. https://doi.org/10.1093/ectcc-jc/jjaa105 [in press].

[78] Valenti M, Facheris P, Pavia G, et al. Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab. Dermatol Ther 2020:e13708.

[79] Tursi A, Angarano G, Monno L, et al. COVID-19 infection in Crohn's disease under treatment with adalimumab. Gut 2020;69(7):1364–5.